Article Highlights

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

What sets the MiniMed 780G apart

The MiniMed 780G is a tubed insulin pump designed for users who want high-level automation and strong real-world results. Its adaptive algorithm, easy-to-use interface, and reliable AA battery make it a dependable option for daily diabetes care.

When paired with the Guardian 4 CGM, SmartGuard activates a hybrid closed-loop system that automatically adjusts basal insulin and delivers frequent correction boluses. The result is improved glucose stability with less daily effort.

The MiniMed 780G system works exclusively with the Medtronic Guardian 4 CGM and is not compatible with other CGM brands. If you currently use a different CGM, we recommend exploring other pump options through our Guide to insulin pumps in Canada.

Key features and design

The MiniMed 780G is engineered with daily usability in mind, combining automation, durability, and comfort. Key features include:

  • Automated insulin adjustments every five minutes
  • Meal Detection that responds to underestimated or missed carbohydrates
  • Personalized glucose targets as low as 100 mg/dL
  • Large 300-unit reservoir for higher insulin needs
  • Standard AA battery lasting up to three weeks
  • IPX8 water protection for up to 12 feet for 24 hours
  • Bluetooth connectivity for CGM and smartphone apps

At a glance

FeatureDetails
Weight102 g
Dimensions9.68 × 5.36 × 2.49 cm
Reservoir300 units
BatteryStandard AA (lithium, alkaline, or rechargeable)
Battery lifeUp to 3 weeks
Water protectionIPX8 (up to 12 ft for 24 hours)
CGM compatibilityGuardian 4 in Canada
Phone compatibilityAndroid and iOS
Algorithm updatesEvery 5 minutes
Warranty4 years

Eligibility and user requirements

The MiniMed 780G with SmartGuard is approved for people with type 1 diabetes who meet specific safety and clinical criteria.

Approved for:

  • Ages 7 years and older with type 1 diabetes
  • Users needing between 8 and 250 units of insulin per day for SmartGuard automation
  • Pump-only use in manual mode for a broader group of users

Not suitable for:

  • Children under 7 years old for SmartGuard
  • People who use less than 8 or more than 250 units of insulin per day
  • Anyone who cannot safely respond to pump alerts

SmartGuard automation explained

SmartGuard technology predicts glucose trends and adjusts insulin delivery every five minutes to support time in range. The system learns from your patterns and reduces the cognitive load of diabetes management.

SmartGuard features include:

  • Predictive basal adjustments every five minutes
  • Frequent automated correction boluses
  • Meal Detection that responds to rising glucose after missed or underestimated carbs
  • Glucose targets of 100, 110, or 120 mg/dL
  • Adaptive learning based on the previous six days of insulin needs

Data tracking and connectivity

The MiniMed Mobile app and the CareLink platform allow you to access your pump and CGM data in one place, making it easier to understand your glucose patterns and share insights with your care team.

  • View insulin, CGM, and pump data from a combined dashboard
  • Sync automatically to CareLink for cloud-based review
  • Share real-time data with up to five care partners
  • Access reports to support informed decision making

Evidence from research and real use

Published research and real-world data consistently demonstrate the strong performance of the MiniMed 780G.

Reported averages include:

  • Approximately 75 to 76 percent time in range
  • More than 80 percent time in range using recommended settings
  • About 83 percent overnight time in range
  • A1C reductions of about 0.5 to 0.7 percent on average
  • Low hypoglycemia exposure at about 1.8 percent time below range

Costs and coverage in Canada

The cost of using the MiniMed 780G varies depending on insurance and provincial programs.

Pump hardware: Pricing varies by supplier. Contact Medtronic Canada for current information. Includes a four-year warranty.

Monthly pump supplies:

  • Infusion sets (10 to 13 per month): about $200 to $300
  • Reservoirs (10 to 13 per month): about $60 to $100
  • Estimated total: about $260 to $400 per month

Coverage options:

  • Provincial programs vary widely, with many supporting youth and young adults
  • Private insurance often covers part or all of pump and supply costs
  • Out-of-pocket costs depend on your plan and province
For more information on how pump coverage varies by province and territory, visit our Guide to insulin pump coverage in Canada.

Could the 780G work for you?

The MiniMed 780G may be a strong option if you:

  • Want advanced automation and frequent correction support
  • Use or are willing to use the Guardian 4 CGM
  • Prefer a pump powered by a standard AA battery
  • Need a large reservoir for higher insulin use
  • Value mobile app connectivity and caregiver data sharing
  • Want durable design and strong water protection

How to get started

Beginning pump therapy involves coordinated support from your healthcare team and Medtronic.

Typical steps include:

  1. Speaking with your healthcare provider about a prescription and referral
  2. Verifying coverage with your insurance provider or provincial program
  3. Requesting information from Medtronic Canada or your diabetes clinic
  4. Completing training with a diabetes educator and Medtronic support
  5. Starting SmartGuard with guided setup

References

  1. Medtronic Canada. (2022, November). Medtronic receives Health Canada licence for MiniMed™ 780G System. Retrieved from https://news.medtronic.com/
  2. Da Silva, J., et al. (2022). Real-world performance of the MiniMed 780G system. Diabetes Technology & Therapeutics, 24(2), 113–119.
  3. Choudhary, P., et al. (2022). Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT). The Lancet Diabetes & Endocrinology, 10(10), 720–731.

The information in this article is for educational purposes only and should not replace advice from your healthcare provider. Always consult with your diabetes care team before making decisions about diabetes management.

For more information: